Hariri Nosaibah, Qarmali Morad, Fadare Oluwole
1 University of California San Diego, CA, USA.
2 University of Alabama, Birmingham, AL, USA.
Int J Surg Pathol. 2018 Apr;26(2):126-134. doi: 10.1177/1066896917731862. Epub 2017 Sep 27.
The diagnostic distinction between endometrial serous carcinoma (ESC) and endometrial clear-cell carcinoma (CCC) may occasionally be problematic, and one potentially contributing factor is the finding of clear cells in otherwise classic cases of ESC. This study aimed to define the frequency of this finding and comparatively assessed the immunophenotype of the clear cells. A review of 56 cases of ESC identified 8 (14.28%) with clear cells, representing 1% to 20% (median 7.5) of tumoral volume in these cases. In only 3 cases were clear cells discernible at low (×20) magnification. There was no significant difference in stage distribution or age between ESC patients with and without clear cells. The immunophenotypes of ESC-associated clear cells (group 1) were compared with foci of conventional ESC on another tissue block within the same case (group 2; n = 8) as well as a randomly selected cohort of CCC cases (group 3; n = 8). Groups 1 and 2 showed no significant differences regarding p53, ER, PR, Napsin-A, p504S, and hepatocyte nuclear factor 1β (HNF1β) expression, or regarding mitotic indices or Ki67 proliferation rate. In contrast, group 1 cases showed an immunophenotypic profile that was notably different from that of group 3 cases, with the former showing statistically significantly higher/more frequent expression of ER, PR, Ki67, and p53 and lower/less frequent expression of Napsin-A, p504S, and HNF1β. We conclude that clear-cell change is seen in 14% of ESCs and is discernible at low magnification in only 5%; these areas show an immunophenotype that is essentially identical to the associated background conventional ESC and are phenotypically dissimilar to CCC.
子宫内膜浆液性癌(ESC)与子宫内膜透明细胞癌(CCC)之间的诊断区分偶尔会存在问题,一个潜在的影响因素是在其他典型的ESC病例中发现了透明细胞。本研究旨在确定这一发现的频率,并对透明细胞的免疫表型进行比较评估。对56例ESC病例进行回顾,发现8例(14.28%)有透明细胞,这些病例中透明细胞占肿瘤体积的1%至20%(中位数为7.5%)。只有3例在低倍(×20)放大下可辨别出透明细胞。有透明细胞和无透明细胞的ESC患者在分期分布或年龄上无显著差异。将ESC相关透明细胞组(第1组)的免疫表型与同一病例另一组织块上的传统ESC灶(第2组;n = 8)以及随机选择的一组CCC病例(第3组;n = 8)进行比较。第1组和第2组在p53、雌激素受体(ER)、孕激素受体(PR)、Napsin-A、p504S和肝细胞核因子1β(HNF1β)表达方面,以及有丝分裂指数或Ki67增殖率方面均无显著差异。相比之下,第1组病例的免疫表型与第3组病例明显不同,前者ER、PR、Ki67和p53的表达在统计学上显著更高/更频繁,而Napsin-A、p504S和HNF1β的表达更低/更不频繁。我们得出结论,14%的ESC中可见透明细胞改变,仅5%在低倍放大下可辨别;这些区域的免疫表型与相关的背景传统ESC基本相同,且在表型上与CCC不同。